Back to top Open menu arrow
The Journal of Clinical Psychiatry The Journal of Clinical Psychiatry

The Journal of
Clinical Psychiatry
Access icon

This article is available to members only. Please enjoy the abstract for free. Subscribe for instant access to the full article.

This content is restricted to subscribers

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

  1. Discipline of Psychiatry, Adelaide Medical School, University of Adelaide, Australia
  2. Discipline of Psychiatry, Adelaide Medical School, University of Adelaide, Australia
  3. Department of Psychiatry, Faculty of Medicine, Fukuoka University, Fukuoka City, Japan (Hori);
  4. Department of Psychiatry, University of Münster, Münster, Germany (Schwarte, Hohoff, Baune);
  5. Department of Psychiatry, University of Münster, Münster, Germany
  6. Discipline of Psychiatry, Adelaide Medical School, University of Adelaide, Australia
  7. Northern Adelaide Mental Health Service, Salisbury, Australia
  8. Discipline of Psychiatry, Adelaide Medical School, University of Adelaide, Australia
  9. Discipline of Psychiatry, Adelaide Medical School, University of Adelaide, Australia
  10. Hopwood Centre for Neurobiology, Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia
  11. Discipline of Psychiatry, Adelaide Medical School, University of Adelaide, Australia
  12. Department of Psychiatry, University of Münster, Münster, Germany
  13. Department of Psychiatry, Melbourne Medical School, The University of Melbourne, Australia
  14. The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
  15. Corresponding Author: Prof Bernhard Baune, MD, PhD, MPH, MBA, FRANZCP, Department of Psychiatry, University of Münster, Albert-Schweitzer-Campus 1, Building A 9, 48149 Münster, Germany ([email protected]).
  1. World Health Organization. Depression and Other Common Mental Disorders: Global Health Estimates. WHO; 2017.
  2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition. American Psychiatric Publishing; 2013.
  3. Cambridge OR, Knight MJ, Mills N, et al. The clinical relationship between cognitive impairment and psychosocial functioning in major depressive disorder: a systematic review. Psychiatry Res. 2018;269:157–171. PubMed CrossRef
  4. McIntyre RS, Soczynska JZ, Woldeyohannes HO, et al. The impact of cognitive impairment on perceived workforce performance: results from the International Mood Disorders Collaborative Project. Compr Psychiatry. 2015;56:279–282. PubMed CrossRef
  5. Weightman MJ, Knight MJ, Baune BT. A systematic review of the impact of social cognitive deficits on psychosocial functioning in major depressive disorder and opportunities for therapeutic intervention. Psychiatry Res. 2019;274:195–212. PubMed CrossRef
  6. Knight MJ, Baune BT. Cognitive dysfunction in major depressive disorder. Curr Opin Psychiatry. 2018;31(1):26–31. PubMed CrossRef
  7. Knight MJ, Baune BT. Executive function and spatial cognition mediate psychosocial dysfunction in major depressive disorder. Front Psychiatry. 2018;9:539. PubMed CrossRef
  8. Knight MJ, Fourrier C, Lyrtzis E, et al. Cognitive deficits in the THINC-Integrated Tool (THINC-it) are associated with psychosocial dysfunction in patients with major depressive disorder. J Clin Psychiatry. 2018;80(1):18m12472. PubMed CrossRef
  9. Knight MJ, Lyrtzis E, Baune BT. The association of cognitive deficits with mental and physical quality of life in major depressive disorder. Compr Psychiatry. 2020;97:152147. PubMed CrossRef
  10. Pu S, Setoyama S, Noda T. Association between cognitive deficits and suicidal ideation in patients with major depressive disorder. Sci Rep. 2017;7(1):11637. PubMed CrossRef
  11. Roca M, Vives M, López-Navarro E, et al. Cognitive impairments and depression: a critical review. Actas Esp Psiquiatr. 2015;43(5):187–193. PubMed
  12. Prévot T, Sibille E. Altered GABA-mediated information processing and cognitive dysfunctions in depression and other brain disorders. Mol Psychiatry. 2021;26(1):151–167. PubMed CrossRef
  13. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917. PubMed CrossRef
  14. Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016;21(12):1696–1709. PubMed CrossRef
  15. Knight MJ, Mills NT, Baune BT. Contemporary methods of improving cognitive dysfunction in clinical depression. Expert Rev Neurother. 2019;19(5):431–443. PubMed CrossRef
  16. Chiu WC, Su YP, Su KP, et al. Recurrence of depressive disorders after interferon-induced depression. Transl Psychiatry. 2017;7(2):e1026. PubMed CrossRef
  17. Fourrier C, Singhal G, Baune BT. Neuroinflammation and cognition across psychiatric conditions. CNS Spectr. 2019;24(1):4–15. PubMed CrossRef
  18. Köhler O, Benros ME, Nordentoft M, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014;71(12):1381–1391. PubMed CrossRef
  19. Abbasi SH, Hosseini F, Modabbernia A, et al. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J Affect Disord. 2012;141(2–3):308–314. PubMed CrossRef
  20. Akhondzadeh S, Jafari S, Raisi F, et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety. 2009;26(7):607–611. PubMed CrossRef
  21. Müller N, Schwarz MJ, Dehning S, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 2006;11(7):680–684. PubMed CrossRef
  22. Hashemian F, Majd M, Hosseini S, et al. A randomized, double-blind, placebo-controlled trial of celecoxib augmentation of sertraline in the treatment of a drug-naive women with major depression. Klin Psikofarmakol Bul. 2011;21:S183–S184.
  23. Rosenblat JD, Kakar R, McIntyre RS. The cognitive effects of antidepressants in major depressive disorder: a systematic review and meta-analysis of randomized clinical trials. Int J Neuropsychopharmacol. 2015;19(2):pyv082. PubMed CrossRef
  24. Skvarc DR, Berk M, Byrne LK, et al. Post-operative cognitive dysfunction: an exploration of the inflammatory hypothesis and novel therapies. Neurosci Biobehav Rev. 2018;84:116–133. PubMed CrossRef
  25. Fourrier C, Sampson E, Mills NT, et al. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo. Trials. 2018;19(1):447. PubMed CrossRef
  26. Baune BT, Sampson E, Louise J, et al. No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: a 6-week double-blind placebo controlled randomized trial. Eur Neuropsychopharmacol. 2021;53:34–46. PubMed CrossRef
  27. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22–33, quiz 34–57. PubMed
  28. Mills NT, Sampson E, Fourrier C, et al. Clinical switching strategies of various antidepressants to vortioxetine in the PREDDICT trial. Int J Neuropsychopharmacol. 2020;24(4):314–321. PubMed
  29. McIntyre RS, Best MW, Bowie CR, et al. The THINC-Integrated Tool (THINC-it) screening assessment for cognitive dysfunction: validation in patients with major depressive disorder. J Clin Psychiatry. 2017;78(7):873–881. PubMed CrossRef
  30. Smith EE. Choice reaction time: an analysis of the major theoretical positions. Psychol Bull. 1968;69(2):77–110. PubMed CrossRef
  31. Owen AM, McMillan KM, Laird AR, et al. N-back working memory paradigm: a meta-analysis of normative functional neuroimaging studies. Hum Brain Mapp. 2005;25(1):46–59. PubMed CrossRef
  32. Baune BT, Brignone M, Larsen KG. A network meta-analysis comparing effects of various antidepressant classes on the digit symbol substitution test (DSST) as a measure of cognitive dysfunction in patients with major depressive disorder. Int J Neuropsychopharmacol. 2018;21(2):97–107. PubMed CrossRef
  33. Reitan RM. The relation of the trail making test to organic brain damage. J Consult Psychol. 1955;19(5):393–394. PubMed CrossRef
  34. OECD JRC European Commission. Handbook on Constructing Composite Indicators: Methodology and User Guide. OECD Publishing; 2008.
  35. Mazziotta M, Pareto A. Normalization methods for spatio-temporal analysis of environmental performance: revisiting the Min-Max method. Environmetrics. 2022;33(5):e2730. CrossRef
  36. Rosenberg JM, Beymer PN, Anderson DJ, et al. tidyLPA: an R package to easily carry out latent profile analysis (LPA) using open-source or commercial software. J Open Source Softw. 2018;3(30):978. CrossRef
  37. Dziak JJ, Dierker LC, Abar B. The interpretation of statistical power after the data have been gathered. Curr Psychol. 2020;39(3):870–877. PubMed CrossRef
  38. Molenberghs G, Thijs H, Jansen I, et al. Analyzing incomplete longitudinal clinical trial data. Biostatistics. 2004;5(3):445–464. PubMed CrossRef
  39. Bates D, Maechler M, Bolker B, et al. Fitting linear mixed-effects models using lme4. J Stat Softw. 2015;67(1):1–48. CrossRef
  40. Kuznetsova A, Brockhoff PB, Christensen RHB. {lmerTest} package: tests in linear mixed effects models. J Stat Softw. 2017;82(13):1–26. CrossRef
  41. Australian Qualifications Framework Council. Australian Qualifications Framework Second Edition January 2013. Australian Qualifications Framework Council; 2013.
  42. Iovieno N, Papakostas GI, Feeney A, et al. Vortioxetine versus placebo for major depressive disorder: a comprehensive analysis of the clinical trial dataset. J Clin Psychiatry. 2021;82(4):20r13682. PubMed CrossRef
  43. Bang-Andersen B, Ruhland T, Jørgensen M, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011;54(9):3206–3221. PubMed CrossRef
  44. Dale E, Zhang H, Leiser SC, et al. Vortioxetine disinhibits pyramidal cell function and enhances synaptic plasticity in the rat hippocampus. J Psychopharmacol. 2014;28(10):891–902. PubMed CrossRef
  45. Dale E, Grunnet M, Pehrson AL, et al. The multimodal antidepressant vortioxetine may facilitate pyramidal cell firing by inhibition of 5-HT3 receptor expressing interneurons: an in vitro study in rat hippocampus slices. Brain Res. 2018;1689:1–11. PubMed CrossRef
  46. Rajkowska G, Miguel-Hidalgo JJ, Wei J, et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry. 1999;45(9):1085–1098. PubMed CrossRef
  47. Campbell S, Marriott M, Nahmias C, et al. Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am J Psychiatry. 2004;161(4):598–607. PubMed CrossRef
  48. Konsman JP, Parnet P, Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci. 2002;25(3):154–159. PubMed CrossRef
  49. Liddelow SA, Guttenplan KA, Clarke LE, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541(7638):481–487. PubMed CrossRef
  50. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122(3):787–795. PubMed CrossRef
  51. Talmon M, Rossi S, Pastore A, et al. Vortioxetine exerts anti-inflammatory and immunomodulatory effects on human monocytes/macrophages. Br J Pharmacol. 2018;175(1):113–124. PubMed CrossRef
  52. Hayley S, Hakim AM, Albert PR. Depression, dementia and immune dysregulation. Brain. 2021;144(3):746–760. PubMed CrossRef
  53. Capone ML, Tacconelli S, Di Francesco L, et al. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat. 2007;82(1-4):85–94. PubMed CrossRef
  54. Benhamou M, Gossec L, Dougados M. Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs’ treatment effect on C-reactive protein. Rheumatology (Oxford). 2010;49(3):536–541. PubMed CrossRef
  55. Gong L, Thorn CF, Bertagnolli MM, et al. Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012;22(4):310–318. PubMed CrossRef
  56. Maes M. Targeting cyclooxygenase-2 in depression is not a viable therapeutic approach and may even aggravate the pathophysiology underpinning depression. Metab Brain Dis. 2012;27(4):405–413. PubMed CrossRef
  57. Chang HH, Lee IH, Gean PW, et al. Treatment response and cognitive impairment in major depression: association with C-reactive protein. Brain Behav Immun. 2012;26(1):90–95. PubMed CrossRef
  58. Lane P. Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches. Pharm Stat. 2008;7(2):93–106. PubMed CrossRef

Save Save

Share Share

Cite Cite

Read the Current Issue

Vol 85, 2024 3

Can Our Collective Experiences As Clinicians Improve Mental Health Care?

SSRI Discontinuation and AUD Relapse

Reproductive Pharmacovigilance and Best Practices

Olanzapine and Mirtazapine for Cancer-Related Anorexia

Economic Impact of Cognitive Impairment and Negative Symptoms in Schizophrenia

Functional Unblinding in Pivotal Studies and the Future of Psychedelic Medicine
View current Issue

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe